Biomarkers in Cancer Staging, Prognosis and Treatment Selection
暂无分享,去创建一个
[1] B. Shapiro,et al. Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.
[2] F. Collins,et al. Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.
[3] G. Kovacs,et al. Alteration of mitochondrial DNA in human oncocytomas , 1989, Genes, chromosomes & cancer.
[4] The use of CA15.3 as a serum tumour marker in breast carcinoma. , 1991, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[5] L. E. McDonald,et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[6] C R Cantor,et al. Immuno-PCR: very sensitive antigen detection by means of specific antibody-DNA conjugates. , 1992, Science.
[7] M. Pike,et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. , 1994, Cancer research.
[8] J. Herman,et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[9] R H Hruban,et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. , 1995, The New England journal of medicine.
[10] J. Herman,et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.
[11] N. Mueller. Overview: viral agents and cancer. , 1995, Environmental health perspectives.
[12] C. Boshoff,et al. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells , 1995, Nature Medicine.
[13] J. Herman,et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[14] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[15] D. Alberts,et al. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[16] Peter Devilee,et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients , 1997, Nature Genetics.
[17] G. S. Johnson,et al. An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.
[18] F. Révillion,et al. ERBB2 oncogene in human breast cancer and its clinical significance. , 1998, European journal of cancer.
[19] J N Weinstein,et al. Fishing Expeditions , 1998, Science.
[20] Bert Vogelstein,et al. Somatic mutations of the mitochondrial genome in human colorectal tumours , 1998, Nature Genetics.
[21] M. King,et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. , 1998, JAMA.
[22] Roger Brent,et al. Postgenomic protein analysis: The next bend in the river , 1998, Nature Biotechnology.
[23] J. Jen,et al. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. , 1998, Journal of the National Cancer Institute.
[24] E Gabrielson,et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[25] R. Davis,et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[26] J. Weinstein. Fishing expeditions [6] , 1998 .
[27] D. Sherer,et al. Automated cervical cytology: meta-analyses of the performance of the PAPNET system. , 1999, Obstetrical & gynecological survey.
[28] J. Herman,et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. , 1999, Journal of the National Cancer Institute.
[29] J. Mesirov,et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.
[30] J. Califano,et al. Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. , 1999, Journal of the National Cancer Institute.
[31] N. Sampas,et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling , 2000, Nature.
[32] J. Herman,et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. , 2000, Cancer research.
[33] Scar,et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.
[34] S. Groshen,et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] J. Califano,et al. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] J. Weinstein. Pharmacogenomics--teaching old drugs new tricks. , 2000, The New England journal of medicine.
[37] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[38] E. Petricoin,et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines , 2000, Electrophoresis.
[39] R. Elashoff,et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. , 2000, Cancer research.
[40] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[41] J. Gray,et al. Genome changes and gene expression in human solid tumors. , 2000, Carcinogenesis.
[42] Regulatory issues related to marker development. , 2000, Urologic oncology.
[43] J. Jen,et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. , 2000, Science.
[44] S. Chevret,et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. , 2001, The Journal of investigative dermatology.
[45] M S Pepe,et al. Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.
[46] J. Jen,et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. , 2001, Cancer research.
[47] N. Bianchi,et al. Mitochondrial genome instability in human cancers. , 2001, Mutation research.
[48] D. Sidransky,et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. , 2001, Journal of the National Cancer Institute.
[49] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[50] C. Paweletz,et al. New approaches to proteomic analysis of breast cancer , 2001, Proteomics.
[51] L. Peloso,et al. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients. , 2001, Cancer journal.
[52] D. Botstein,et al. Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[53] Mary V. Relling,et al. Pharmacogenetics and cancer therapy , 2001, Nature Reviews Cancer.
[54] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[55] V. Patel,et al. New approaches to the understanding of the molecular basis of oral cancer. , 2001, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.
[56] Evaluation of alternative approaches for imaging cellular growth. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[57] C. Sotiriou,et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer , 2002, Breast Cancer Research.
[58] P. Ravdin,et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] E. Petricoin,et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.
[60] S M Hanash,et al. Proteomic Approaches within the NCI Early Detection Research Network for the Discovery and Identification of Cancer Biomarkers , 2001, Annals of the New York Academy of Sciences.
[61] Frank Dudbridge,et al. Haplotype tagging for the identification of common disease genes , 2001, Nature Genetics.
[62] J. Herman,et al. A gene hypermethylation profile of human cancer. , 2001, Cancer research.
[63] C. Allis,et al. Translating the Histone Code , 2001, Science.
[64] E. Petricoin,et al. Proteomics of human breast ductal carcinoma in situ. , 2002, Cancer research.
[65] Nan Hu,et al. 2D Differential In-gel Electrophoresis for the Identification of Esophageal Scans Cell Cancer-specific Protein Markers* , 2002, Molecular & Cellular Proteomics.
[66] S. Gutman. Regulatory issues in tumor marker development. , 2002, Seminars in oncology.
[67] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[68] M. Hammond,et al. Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. , 2002, Seminars in oncology.
[69] David Botstein,et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[70] C. Wheeler,et al. A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.
[71] E. Petricoin,et al. Clinical proteomics: translating benchside promise into bedside reality , 2002, Nature Reviews Drug Discovery.
[72] Mukesh Verma,et al. The promise of biomarkers in cancer screening and detection. , 2002, Trends in molecular medicine.
[73] E. Kohn,et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer , 2002, Proteomics.
[74] Marek Kimmel,et al. Haplotype and linkage disequilibrium architecture for human cancer-associated genes. , 2002, Genome research.
[75] Bradley James Erickson,et al. Computer-Aided Detection and Diagnosis at the Start of the Third Millennium , 2002, Journal of Digital Imaging.
[76] Donald L Weaver,et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] Ji Huang,et al. [Serial analysis of gene expression]. , 2002, Yi chuan = Hereditas.
[78] N. Anderson,et al. The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.
[79] J. Weinstein. 'Omic' and hypothesis-driven research in the molecular pharmacology of cancer. , 2002, Current opinion in pharmacology.
[80] M. Spitz,et al. p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. , 2002, Journal of the National Cancer Institute.
[81] S. Lee,et al. Genetic polymorphisms of XRCC1 and risk of gastric cancer. , 2002, Cancer letters.
[82] F. Sato,et al. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon , 2002, Oncogene.
[83] D. Sidransky,et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. , 2002, Cancer research.
[84] David Sidransky,et al. Emerging molecular markers of cancer , 2002, Nature Reviews Cancer.
[85] M. Villalobos,et al. Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer. , 2002, European urology.
[86] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[87] J. Gray,et al. The genetics and genomics of cancer , 2003, Nature Genetics.
[88] A. Nakao,et al. Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients , 2003, International journal of cancer.
[89] C. Mirkin,et al. Nanoparticle-Based Bio-Bar Codes for the Ultrasensitive Detection of Proteins , 2003, Science.
[90] S. Leung,et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[91] M. Bruchez,et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots , 2003, Nature Biotechnology.
[92] L. Kostakoglu,et al. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[93] L. Sobin,et al. TNM: evolution and relation to other prognostic factors. , 2003, Seminars in surgical oncology.
[94] Paul Cairns,et al. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. , 2003, Cancer research.
[95] B. Weigl,et al. Lab-on-a-chip for drug development. , 2003, Advanced drug delivery reviews.
[96] E. Petricoin,et al. Early detection: Proteomic applications for the early detection of cancer , 2003, Nature Reviews Cancer.
[97] L. Knight,et al. Radiopharmaceuticals for targeting the angiogenesis marker αvβ3 , 2003 .
[98] Yingdong Zhao,et al. Molecular Differentiation of High- and Moderate-Grade Human Prostate Cancer by cDNA Microarray Analysis , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[99] Philip M. Long,et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[100] K. Togashi. Ovarian cancer: the clinical role of US, CT, and MRI , 2003, European Radiology.
[101] Tiny Transistors Scout for Cancer , 2003, Science.
[102] R. Rosell,et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. , 2003, Cancer letters.
[103] E. Lander,et al. A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.
[104] R. Salunga,et al. Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[105] J. Satagopan,et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment , 2003, Breast Cancer Research.
[106] T. Fojo,et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[107] Peter E Barker,et al. Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). , 2003, Annals of the New York Academy of Sciences.
[108] Jianfeng Xu,et al. Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk , 2003, International journal of cancer.
[109] William C Reinhold,et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[110] S James Adelstein,et al. Molecular targeting with radionuclides: state of the science. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[111] Igor L. Medintz,et al. Self-assembled nanoscale biosensors based on quantum dot FRET donors , 2003, Nature materials.
[112] H. Kuwano,et al. High frequency of DAP-kinase gene promoter methylation in colorectal cancer specimens and its identification in serum. , 2003, Cancer letters.
[113] R. Bold,et al. Utility of tumor markers in determining resectability of pancreatic cancer. , 2003, Archives of surgery.
[114] L. Lesko,et al. Microarray data—the US FDA, industry and academia , 2003, Nature Biotechnology.
[115] Caroline Seydel,et al. Quantum Dots Get Wet , 2003, Science.
[116] D. Mavroudis,et al. Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[117] Syed Mohsin,et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.
[118] Lale Kostakoglu,et al. Clinical role of FDG PET in evaluation of cancer patients. , 2003, Radiographics : a review publication of the Radiological Society of North America, Inc.
[119] Peter E. Barker,et al. Cancer Biomarker Validation: Standards and Process , 2003 .
[120] E. Ben-Ari. Nanoscale quantum dots hold promise for cancer applications. , 2003, Journal of the National Cancer Institute.
[121] Michael Bittner,et al. Gene-expression profiling in human cutaneous melanoma , 2003, Oncogene.
[122] S. Leung,et al. Pretherapy quantitative measurement of circulating Epstein–Barr virus DNA is predictive of posttherapy distant failure in patients with early‐stage nasopharyngeal carcinoma of undifferentiated type , 2003, Cancer.
[123] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[124] F. Blankenberg,et al. Feasibility of 99mTc-annexin V for repetitive detection of apoptotic tumor response to chemotherapy: an experimental study using a rat tumor model. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[125] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[126] D. Ransohoff. Rules of evidence for cancer molecular-marker discovery and validation , 2004, Nature Reviews Cancer.
[127] Ruud H. Brakenhoff,et al. Dissecting the metastatic cascade , 2004, Nature Reviews Cancer.
[128] K. Pantel,et al. Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives , 2004, Breast Cancer Research.
[129] K. Awai,et al. Pulmonary nodules at chest CT: effect of computer-aided diagnosis on radiologists' detection performance. , 2004, Radiology.
[130] Nirag Jhala,et al. Diagnostic Markers That Distinguish Colon and Ovarian Adenocarcinomas: Identification by Genomic, Proteomic, and Tissue Array Profiling , 2004 .
[131] S. Nelson,et al. DNA-microarray analysis of brain cancer: molecular classification for therapy , 2004, Nature Reviews Neuroscience.
[132] S. Bates,et al. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. , 2004, Current pharmaceutical design.
[133] G. Bepler,et al. Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients , 2004, Clinical Cancer Research.
[134] Claire Holloway,et al. Enumeration of Circulating Tumor Cells in the Blood of Breast Cancer Patients After Filtration Enrichment: Correlation with Disease Stage , 2004, Breast Cancer Research and Treatment.
[135] Tanja Fehm,et al. Circulating Tumor Cells in Patients with Breast Cancer Dormancy , 2004, Clinical Cancer Research.
[136] Margarita L Zuley,et al. Can computer-aided detection with double reading of screening mammograms help decrease the false-negative rate? Initial experience. , 2004, Radiology.
[137] H. Lenz. The use and development of germline polymorphisms in clinical oncology. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[138] David C Christiani,et al. High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines , 2004, Oncogene.
[139] Gangning Liang,et al. Preferential response of cancer cells to zebularine. , 2004, Cancer cell.
[140] M. Fukuoka,et al. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. , 2004, Lung cancer.
[141] S. Bates,et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. , 2004, Blood.
[142] Manel Esteller,et al. DNA methylation and cancer therapy: new developments and expectations , 2005, Current opinion in oncology.
[143] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[144] F. Hoek,et al. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer , 1995, Journal of Cancer Research and Clinical Oncology.
[145] Jason A. Papin,et al. Reconstruction of cellular signalling networks and analysis of their properties , 2005, Nature Reviews Molecular Cell Biology.